RÉSUMÉ
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients. Clinical Trial Registration: Clinicaltrials.gov, NCT03979313, https://clinicaltrials.gov/ct2/show/NCT03979313.
Sujet(s)
Infections à virus respiratoire syncytial , Virus respiratoire syncytial humain , Infections de l'appareil respiratoire , Enfant , Humains , Nourrisson , Anticorps monoclonaux humanisés/usage thérapeutique , Infections à virus respiratoire syncytial/traitement médicamenteux , Infections à virus respiratoire syncytial/prévention et contrôle , Infections de l'appareil respiratoire/traitement médicamenteux , Infections de l'appareil respiratoire/prévention et contrôle , SaisonsSujet(s)
Anticorps monoclonaux humanisés , Antiviraux , Maladies néonatales , Prématuré , Infections à virus respiratoire syncytial , Humains , Nourrisson , Nouveau-né , Anticorps monoclonaux humanisés/usage thérapeutique , Antiviraux/usage thérapeutique , Hospitalisation , Palivizumab , Infections à virus respiratoire syncytial/prévention et contrôle , Infections à virus respiratoire syncytial/traitement médicamenteux , Naissance à terme , Maladies néonatales/traitement médicamenteux , Maladies néonatales/prévention et contrôleRÉSUMÉ
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. METHODS: We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or placebo before the start of an RSV season. The primary efficacy end point was medically attended RSV-associated lower respiratory tract infection through 150 days after the injection. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after the injection. RESULTS: A total of 1490 infants underwent randomization: 994 were assigned to the nirsevimab group and 496 to the placebo group. Medically attended RSV-associated lower respiratory tract infection occurred in 12 infants (1.2%) in the nirsevimab group and in 25 infants (5.0%) in the placebo group; these findings correspond to an efficacy of 74.5% (95% confidence interval [CI], 49.6 to 87.1; P<0.001) for nirsevimab. Hospitalization for RSV-associated lower respiratory tract infection occurred in 6 infants (0.6%) in the nirsevimab group and in 8 infants (1.6%) in the placebo group (efficacy, 62.1%; 95% CI, -8.6 to 86.8; P = 0.07). Among infants with data available to day 361, antidrug antibodies after baseline were detected in 58 of 951 (6.1%) in the nirsevimab group and in 5 of 473 (1.1%) in the placebo group. Serious adverse events were reported in 67 of 987 infants (6.8%) who received nirsevimab and in 36 of 491 infants (7.3%) who received placebo. CONCLUSIONS: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection. (Funded by MedImmune/AstraZeneca and Sanofi; MELODY ClinicalTrials.gov number, NCT03979313.).
Sujet(s)
Anticorps monoclonaux humanisés/usage thérapeutique , Antiviraux/usage thérapeutique , Maladies du prématuré/prévention et contrôle , Prématuré , Infections à virus respiratoire syncytial/prévention et contrôle , Anticorps monoclonaux humanisés/administration et posologie , Anticorps monoclonaux humanisés/effets indésirables , Antiviraux/administration et posologie , Antiviraux/effets indésirables , Calendrier d'administration des médicaments , Femelle , Humains , Nourrisson , Nouveau-né , Injections musculaires , Estimation de Kaplan-Meier , MâleRÉSUMÉ
Over the past 10 years there has been an increase in the number of vaccine clinical studies conducted in resource limited countries. These include vaccine trials for diseases such as malaria and dengue fever which are endemic to many low and lower-middle income countries. Concurrent with the increase in the number of trials, has been the increase and improvement in local infrastructure to enable the appropriate conduct and oversight of trials in these settings, including strengthening of local scientific capabilities, ethical and regulatory oversight. While significant advances have been made, there remain gaps to be addressed including strengthening pharmacovigilance in these regions. There are also opportunities to establish novel collaborations to address diseases specific to these populations including strengthening local manufacturers, new ways to engage established large pharmaceutical companies and leveraging established global infrastructure and pathways to develop innovative products beyond vaccines.